Search
Tobevibart
go.drugbank.com/drugs/DB18986InvestigationalTobevibart is under investigation in clinical trial NCT05612581 (A Platform Study to Evaluate Investigational Therapies in Chronic Hepatitis B Infection).
AGI-134
go.drugbank.com/drugs/DB19005InvestigationalAGI-134 is under investigation in clinical trial NCT03593226 (Study to Evaluate Safety & Tolerability of AGI-134 in Solid Tumour).
Substance P
go.drugbank.com/drugs/DB19198InvestigationalSubstance P is under investigation in clinical trial NCT03738878 (Mechanism(s) Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 1).
Gamma-Arsono-Beta, Gamma-Methyleneadenosine-5'-Diphosphate
go.drugbank.com/drugs/DB02937ExperimentalAdenine nucleotide containing one phosphate group esterified to the sugar moiety in the 2'-, 3'-, or 5'-position. [PubChem]
Ansofaxine
go.drugbank.com/drugs/DB15052InvestigationalAnsofaxine is under investigation in clinical trial NCT02271412 (Multiple Ascending Dose Study in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY03005).
Zimlovisertib
go.drugbank.com/drugs/DB15143InvestigationalPF-06650833 is under investigation in clinical trial NCT02609139 (Study to Evaluate Pharmacokinetics of A Modified Release Formulation of PF-06650833 in Healthy Subjects).
Quilizumab
go.drugbank.com/drugs/DB15176InvestigationalQuilizumab is under investigation in clinical trial NCT01160861 (A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MEMP1972A in Patients With Allergic Rhinitis).
Ziritaxestat
go.drugbank.com/drugs/DB15403InvestigationalZiritaxestat is under investigation in clinical trial NCT03798366 (A Clinical Study to Test How Effective and Safe GLPG1690 is for Patients With Systemic Sclerosis).
GSK2798745
go.drugbank.com/drugs/DB16033InvestigationalGSK2798745 is under investigation in clinical trial NCT03372603 (A Study to Assess the Effectiveness and Side Effects of GSK2798745 in Participants With Chronic Cough).
Emerfetamab
go.drugbank.com/drugs/DB18474InvestigationalEmerfetamab is a bispecific T cell engager antibody construct with a half-life extension Fc moiety capable of binding to the neonatal Fc receptor.